Navigating the Regulatory Complexities of Orphan Drugs: Know the unwritten rules of designations and what’s next
November 2, 2017 - November 2, 2017
Without knowing the unwritten rules of orphan drug designations and what comes next, your application could be waitlisted, your market exclusivity could be at risk, and patient access to your rare disease treatment could be delayed.
Watch this webinar to learn about the potential pitfalls that can accompany orphan drug development and how you can avoid them.
This webinar will explore:
- How to be among the top 30% of designation applicants and attain market exclusivity
- What’s Next: Tax breaks and other advantages of special designations
- Global orphan drug opportunities and regulatory trends beyond the US and EU